Lyell Immunopharma, Inc.
LYEL Healthcare Biotechnology
Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024. In the quarter to June 2026, revenue fell 50.0%, EPS grew 33.6% and free cash flow grew 1.31%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow LYEL
Lyell Immunopharma, Inc. (LYEL) P/E ratio
Lyell Immunopharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 21 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ADCT ADC Therapeutics SA compare | n/m |
| LYEL Lyell Immunopharma, Inc. | n/m |
| RNAC Cartesian Therapeutics, Inc. compare | n/m |
| IVVD Invivyd, Inc. compare | n/m |
| LRMR Larimar Therapeutics, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | n/m |
| PRQR ProQR Therapeutics N.V. compare | n/m |
| CGEN Compugen Ltd. compare | 5.2× |
| NAGE Niagen Bioscience, Inc. compare | 12.5× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)